Clinical Trials Logo

Aggression clinical trials

View clinical trials related to Aggression.

Filter by:

NCT ID: NCT06093841 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Start date: November 2023
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.

NCT ID: NCT06047587 Recruiting - Aggression Clinical Trials

Virtual Reality Training for Aggression Control

Start date: April 18, 2023
Phase: N/A
Study type: Interventional

The main goal of this randomized controlled trial is to investigate the effectiveness of VR-TRAC (Virtual Reality TRaining for Aggression Control) for reducing aggression in a prison-based population. The study-design is a single-blind randomized controlled trial, comparing VR-TRAC to waiting-list control condition (WL). 128 male detainees with aggression regulation problems in the last month (measured with the Aggression Questionnaire [AQ]) and a minimum age of 18 years, recruited from the Penitentiary Institution (P.I.) Vught, the Netherlands will participate in this study. They are randomly allocated to VR-TRAC or control condition WL. The treatment group fills in questionnaires, participates in role-plays and follows the VR-TRAC. The control group filles in the same questionnaires as the treatment group and also participates in the role-plays, but does not participate in the VR-TRAC. Participants receive Care As Usual (CAU) when necessary. To measure the effect of VR-TRAC on aggression, three different types of measurements are used: staff observation, self-report and performance-based. Self-report questionnaires will be scored on three different moments during the study: before the treatment starts, at the end of the treatment, and two- months after the treatment ended. Throughout the sessions, participants are also asked to answer questions to evaluate the sessions. Lastly, to measure the effectiveness of the skills trained in the VR-TRAC, performance-based assessments (role-play tests and vignettes) will be conducted before and after the treatment period.

NCT ID: NCT06032520 Recruiting - Aggression Clinical Trials

The Effectiveness of Forensic Outpatient Systemic Therapy: a Multiple Case Experimental Design

FAST
Start date: August 25, 2023
Phase:
Study type: Observational

The purpose of this study is to investigate the effectiveness and mediators of Forensic Outpatient Systemic Therapy (FAST).

NCT ID: NCT05978141 Recruiting - Clinical trials for Angioimmunoblastic T-cell Lymphoma

A Registry for People With T-cell Lymphoma

Start date: July 27, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

NCT ID: NCT05946720 Completed - Aggression Clinical Trials

Aggression From the Perspective of Patients and Nurses

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

The research, was planned in a randomized controlled design, aiming to evaluate the effect of the training given to nurses working in psychiatric clinics on the use of aggression and BVC (Broset Violence Checklist) on the nurses' perceptions of aggression and the compliance of the use of BVC, which they evaluated for the patients watched in the videos, with the BVC determined by expert opinion. The study was conducted in Adana Doctor Ekrem Tok Mental Health and Diseases Hospital between July 2021 and April 2022. A total of 97 nurses working in psychiatric clinics, 47 in the training group and 50 in the comparison group, participated in the study. A pre-test was administered to the nurses and nurses in the training group were randomized and given training including aggression and BVC use. After the training, a post-test was administered to all nurses.

NCT ID: NCT05928247 Recruiting - Aggression Clinical Trials

Manualized Assessment and Treatment Model of Challenging Behavior

Start date: April 8, 2024
Phase: N/A
Study type: Interventional

Despite decades of mounting single-case-design evidence for the efficacy of applied behavior analysis (ABA) and other approaches for the assessment and treatment of challenging behavior, an evidence-based comprehensive approach remains to exist. The current study will collect test the efficacy of a standardized manual for assessing and treating challenging behavior for individuals with severe and mild challenging behavior.

NCT ID: NCT05925101 Recruiting - Aggression Clinical Trials

Basic and Applied Research on Extinction Bursts

Start date: July 7, 2023
Phase: N/A
Study type: Interventional

Although highly effective, treatments like FCT include extinction, which can have adverse side effects. The extinction burst, an increase in the frequency or intensity of destructive behavior at the start of treatment, is the most common side effect of extinction, and can increase the risk of harm to the patient and others. The goal of the current study is to evaluate the prevalence of extinction bursts when various parameters of reinforcement (i.e., rate, magnitude, quality) are manipulated.

NCT ID: NCT05895513 Not yet recruiting - Clinical trials for Intermittent Explosive Disorder

Pimavanserin and Aggression and Social Cognition.

Start date: January 2024
Phase: Phase 2
Study type: Interventional

The investigators are studying how certain drugs can reduce anger outbursts in people with anger problems. In this study the investigators seek to determine if a single 34 mg (two 17 mg tablets) oral dose of the 5-HT2a receptor blocker, pimavanserin, will reduce aggressive responding in individuals with impulsive aggression (Intermittent Explosive Disorder: IED) on a laboratory task that assesses aggression (Taylor Aggression Paradigm: TAP). We will also be examining how this drug impacts hostile social cognition e.g., hostile attribution). If pimvanserin reduces aggression in this study a next step would be a placebo-controlled treatment trial of pimavanserin in study participants with IED. Participation will first involve a remote (e.g., TEAMS) screening session. If potential study participants appear eligible they will come into the lab for an in-person session where participants will complete interviews and questionnaires and have a medical evaluation (including a physical exam, electrocardiogram, and screens for alcohol and drug use). During the next study session, participants will complete a diagnostic interview and a series of questionnaires, all of which can all take place on-line. During the next two sessions (which will be in-person) participants will undergo two (2) study sessions during which study participants will be given a study drug (orally). The drug given, pimavanserin, is currently available and is known to block serotonin receptors thought to be involved in regulating anger. After participants take the study drug, study participants will complete questionnaires and computer tasks for assessment of aggression and of hostile social cognition. Each of these two in-person study sessions will take at least eight (8) hours. A final on-line session will be done to make certain the investigators have all the data required by the study protocol.

NCT ID: NCT05887973 Recruiting - Aggression Clinical Trials

Addressing Root Causes for Gun Violence Prevention (ARC-GVP)

Start date: June 27, 2022
Phase:
Study type: Observational

The goal of this study is to help build the evidence base for a locally-relevant youth firearm violence prevention program in Washington D.C., a city experiencing disparities in youth firearm violence outcomes. The main question it aims to answer is: How is youth participation in the summer youth employment program, the True Reasons I Grabbed the Gun Evolved from Risk (The T.R.I.G.G.E.R Project), which is designed to address root causes of gun violence, associated with individual youth behavioral outcomes, including pro-social involvement, aggression, and firearm-related attitudes and behaviors?

NCT ID: NCT05866679 Recruiting - Ovarian Cancer Clinical Trials

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Start date: April 12, 2024
Phase: Phase 1
Study type: Interventional

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.